Telesis Bio IncChange company Symbol lookupSelect an option...TBIO Telesis Bio IncTRIRF Triterras IncAIC Arlington Asset Investment CorpLCID Lucid Group IncAMAT Applied Materials Inc$DWCPAP DJTSM US PaperCMMB Chemomab Therapeutics LtdDLTR Dollar Tree IncBAC Bank of America CorpKW Kennedy-Wilson Holdings IncGo
Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of virtually error-free DNA and mRNA at a useable scale. Its on-market and planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp DBC, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, BioXp DBC kits, Benchtop reagents and Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS). BioXp 3250 system is a push-button, walkaway, end-to-end automated workstation that offers endpoint-ready synthetic DNA in as few as 8 hours and mRNA in less than 24 hours. BioXp DBC is engaged in delivering on-demand enzymatic DNA synthesis with design-to-endpoint-ready synthetic RNA in as few as 24 hours.
|
|
|
|
| |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.